ReN 001

Drug Profile

ReN 001

Alternative Names: CTX 0E03 neural stem cells; ReN-001

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ReNeuron
  • Class Neuroprotectants; Stem cell therapies
  • Mechanism of Action Cell replacements; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Stroke

Most Recent Events

  • 22 Nov 2017 Phase-I development for Stroke (In the elderly) is ongoing in Scotland (Intracerebral, Implant) (ReNeuron Pipeline, November 2017)
  • 31 Oct 2017 ReNeuron plans to submit an IND application to the US FDA for a randomised, placebo-controlled clinical trial for Stroke in the US
  • 31 Oct 2017 Safety and efficacy data from the phase II PISCES II trial in Stroke released by ReNeuron
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top